HDAC-IN-37,2766466-56-0

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

HDAC-IN-37

CAS No. : 2766466-56-0

MCE 国际站：HDAC-IN-37

产品活性：HDAC-IN-37 是一种有效的 HDAC 抑制剂，对 HDAC1、HDAC3、HDAC8 和 HDAC6 的 IC₅₀ 分别为 0.0551 μM、1.24 μM、0.948 μM 和 34.2 μM。HDAC-IN-37 能缓慢诱导组蛋白乙酰化。HDAC-IN-37 抑制细胞由 G1 期向 S 期转变，诱导早期细胞凋亡 (apoptosis)。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics  |  Apoptosis

作用靶点：HDAC  |  Apoptosis

In Vitro: HDAC-IN-37 (compound 9d) exhibits the potent antiproliferative activities on the HCT116, MDA-MB-231, K562 cell lines at IC₅₀s of 0.50, 0.38, 0.12 μM, respectively.
HDAC-IN-37 (0 - 10 μM; 24 hours) significantly induces the accumulation of acetylated histones at H3K9 and H4K5 in HCT-116 cells.
HDAC-IN-37 (0 - 10 μM; 24 hours) induces cell apoptosis in HCT-116 cells by 35.22%, 58.34, 80.7% at 0.5, 1, 5 μM, mainly occurring in early apoptosis.
HDAC-IN-37 (0 - 10 μM; 6, 12, 24 hours) causes G0/G1 phase arrest of HCT-116 cells in a time-dependent manner, effectively preventing cell cycle progression.
HDAC-IN-37 (0, 0.1, 0.5, 1, 5 and 10 μM; 0, 6, 12, 24, 36, 48 hours) down-regulates the levels of CDK2, Cyclin D1 and the up-regulates P21 with dose- and time-dependent manners in HCT-116 cells, and decreases Bcl-2 of Bcl-2 family in dose- and time-dependent manners.

相关产品：MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine  |  SP600125  |  MK-2206 dihydrochloride  |  Etoposide  |  Trichostatin A

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds